tradingkey.logo

FDA Approves Merck’S WELIREG® (Belzutifan) For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Locally Advanced, Unresectable, Or Metastatic Pheochromocytoma Or Paraganglioma (PPGL)

ReutersMay 14, 2025 9:16 PM

- Merck & Co Inc MRK.N:

  • FDA APPROVES MERCK’S WELIREG® (BELZUTIFAN) FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA (PPGL)

  • MERCK & CO INC: WELIREG LABEL CONTAINS A BOXED WARNING THAT EXPOSURE TO WELIREG DURING PREGNANCY CAN CAUSE EMBRYO-FETAL HARM

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles